

➤ **Training courses for 2016**

The UKSCB is involved in organizing a number of training courses in 2016. The first, on reprogramming and iPSC culture will be held on 23-25<sup>th</sup> May and is run in conjunction with EBISC project ([www.ebisc.eu/](http://www.ebisc.eu/)) partners (Roslin Cells and the Sanger Institute), the Harvard Stem Cell Institute and the University of Hatfield. Other courses in iPSC differentiation and a Wellcome Trust iPSC culture course will be announced later this year. Further information can be obtained via the UKSCB enquiries email address [enquiries@ukstemcellbank.org.uk](mailto:enquiries@ukstemcellbank.org.uk)

➤ **UKSCB Technical Forum: workshop on experiences in gene editing**

The [UKSCB](http://www.ukscb.org.uk) is running another technical Forum meeting on 26<sup>th</sup> May 2016 at NIBSC ([www.nibsc.org](http://www.nibsc.org)). The workshop is open to anyone willing to share their experiences in the use of gene editing techniques and is run in conjunction with the Harvard Stem Cell Institute and the EBISC project. Spaces will be limited so please contact UKSCB enquiries email [enquiries@ukstemcellbank.org.uk](mailto:enquiries@ukstemcellbank.org.uk) or call 01707641561.

➤ **3<sup>rd</sup> IABS conference on cell therapy manufacturing and standardisation**

UKSCB is involved in organizing the 3<sup>rd</sup> International Alliance for Biological Standardisation meeting on cell therapy practice in cell therapy, which be held at the Wellcome Collection in London, 2-3 November 2016 ([www.iabs.org/](http://www.iabs.org/)). The meeting has attracted speakers from around the world and is aimed to help draw international consensus on manufacture and standardisation of therapies (a report published from the 2<sup>nd</sup> meeting in 2015 is attached). Spaces will be limited so we advise an early contact with the UKSCB enquiries email [enquiries@ukstemcellbank.org.uk](mailto:enquiries@ukstemcellbank.org.uk) or call 01707641561.

➤ **Update on delivery of clinical grade cell lines**

The Bank has completed due diligence now on 25 of 39 proposed clinical-grade hESC lines approved for deposit by the UK Steering Committee. The EUTCD-Grade cell lines are those that comply with HTA directions making them suitable for use as starting materials for clinical applications under EU regulation. The UKSCB is continuing to undertake this process for a further 6 cell lines and has also received detailed HLA and karyological data from depositors for 26 of the approved lines.

The first Master Cell Bank of a Laboratory-grade variant of an EUTCD-approved cell line (MasterShef 2) and a distribution stock is currently being banked for quality control and safety testing prior to release in summer 2016.

Further details can be found on the Due Diligence page of the [UKSCB website](http://www.ukscb.org.uk).

If you would like to speak with a member of UKSCB staff email us at [enquiries@ukstemcellbank.org.uk](mailto:enquiries@ukstemcellbank.org.uk). We will also be attending the following meetings and workshops this spring and summer: 1) British Society for Gene and Cell Therapy, London, 15<sup>th</sup> April; 2) UCL Stem Cell Training Course, 25-27<sup>th</sup> April; 3) ISSCR, San Francisco, 22-26<sup>th</sup> June; 4) International Stem Cell banking Initiative workshop, San Francisco, 26<sup>th</sup> June; 5) Stem Cells and Gene Therapy, Florence, 18-21<sup>st</sup> October.